Senolytic Drugs Reshape Gut Bacteria in Ways That May Slow Aging

Cellular senescence — the process by which damaged cells stop dividing but resist death — is a central driver of biological aging and age-related diseases. Senotherapeutic agents, including senolytics that clear these zombie cells, have attracted significant research interest. However, their interactions with the gut microbiome, a key regulator of systemic health, have been poorly understood until now.

This study from UCL School of Pharmacy examined the bidirectional relationship between four senotherapeutic compounds — quercetin, fisetin, dasatinib, and sirolimus — and gut microbiota sourced from healthy human donors. Using ex vivo fermentation models and metagenomic analysis, researchers tracked both how the drugs affected bacterial communities and how bacteria metabolized the drugs.

All four compounds favorably shifted the microbiome composition. They increased the abundance of bacteria associated with healthy aging, including Bacteroides fragilis, Bifidobacterium longum, and Veillonella parvula, while decreasing pathogenic species such as Enterococcus faecalis and Streptococcus spp. that are linked to age-related conditions. Notably, quercetin was completely biotransformed by gut bacteria within just six hours, raising questions about its bioavailability and effective dosing. Dasatinib, a chemotherapy-derived senolytic, was the most metabolically stable of the four.

These findings introduce a pharmacobiomics lens to senolytic research — suggesting that the gut microbiome may modulate drug efficacy, and that the drugs themselves may confer additional benefit by reshaping microbial ecology toward a pro-longevity profile.

Caveats include the ex vivo design, which may not fully replicate in vivo gut dynamics, and the use of healthy donor microbiota, which may not represent aged or diseased populations where senolytics are most likely to be used.